Neuroinflammation as a Potential Therapeutic Target in Alzheimer’s Disease

References

• Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8:23. doi:10.1186/s13195-016-0188-8
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7:e12179. doi:10.1002/trc2.12179
   PubMedGoogle Scholar
• Vermunt L, Sikkes S, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15:888–898. doi:10.1016/j.jalz.2019.04.001
   PubMed Web of Science ®Google Scholar
• Jack CJ, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562. doi:10.1016/j.jalz.2018.02.018
   PubMed Web of Science ®Google Scholar
• Hampel H, Cummings J, Blennow K, Gao P, Jack CJ, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021;17:580–589. doi:10.1038/s41582-021-00520-w
   PubMed Web of Science ®Google Scholar
• Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s Disease. Front Immunol. 2020;11:456. doi:10.3389/fimmu.2020.00456
   PubMed Web of Science ®Google Scholar
• Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res Ther. 2021;13:62. doi:10.1186/s13195-021-00795-7
   PubMed Web of Science ®Google Scholar
• Syed YY. Sodium oligomannate: first approval. Drugs. 2020;80:441–444. doi:10.1007/s40265-020-01268-1
   PubMed Web of Science ®Google Scholar
• Dhillon S. Aducanumab: first Approval. Drugs. 2021;81:1437–1443. doi:10.1007/s40265-021-01569-z
   PubMed Web of Science ®Google Scholar
• Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer’s disease. Alzheimers Res Ther. 2019;11:76. doi:10.1186/s13195-019-0529-5
   PubMed Web of Science ®Google Scholar
• Uddin MS, Hasana S, Ahmad J, et al. Anti-neuroinflammatory potential of polyphenols by inhibiting NF-kappaB to halt Alzheimer’s Disease. Curr Pharm Des. 2021;27:402–414. doi:10.2174/1381612826666201118092422
   PubMed Web of Science ®Google Scholar
• Fu WY, Wang X, Ip NY. Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease: mechanisms, drug candidates, and new opportunities. Acs Chem Neurosci. 2019;10:872–879. doi:10.1021/acschemneuro.8b00402
   PubMed Web of Science ®Google Scholar
• Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48:626–632. doi:10.1212/wnl.48.3.626
   PubMed Web of Science ®Google Scholar
• Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002;59:880–886. doi:10.1212/wnl.59.6.880
   PubMed Web of Science ®Google Scholar
• Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology. 2008;70:17–24. doi:10.1212/01.wnl.0000284596.95156.48
   PubMed Web of Science ®Google Scholar
• In TVB, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging. 1998;19:607–611. doi:10.1016/s0197-4580(98)00096-7
   PubMed Web of Science ®Google Scholar
• Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease risk: the MIRAGE Study. Bmc Geriatr. 2005;5:2. doi:10.1186/1471-2318-5-2
   PubMedGoogle Scholar
• The Canadian Study of Health and Aging. Risk factors for Alzheimer’s disease in Canada. Neurology. 1994;44:2073–2080. doi:10.1212/wnl.44.11.2073
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID exposure and risk of Alzheimer’s disease: an updated meta-analysis from cohort studies. Front Aging Neurosci. 2018;10:83. doi:10.3389/fnagi.2018.00083
   PubMed Web of Science ®Google Scholar
• Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23:213–227. doi:10.1177/0891988710383571
   PubMed Web of Science ®Google Scholar
• Misra A, Chakrabarti SS, Gambhir IS. New genetic players in late-onset Alzheimer’s disease: findings of genome-wide association studies. Indian J Med Res. 2018;148:135–144. doi:10.4103/ijmr.IJMR_473_17
   PubMed Web of Science ®Google Scholar
• Novikova G, Kapoor M, Tcw J, et al. Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun. 2021;12:1610. doi:10.1038/s41467-021-21823-y
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ulland TK, Colonna M. TREM2-dependent effects on microglia in Alzheimer’s disease. Front Aging Neurosci. 2018;10:202. doi:10.3389/fnagi.2018.00202
   PubMed Web of Science ®Google Scholar
• Yang J, Fu Z, Zhang X, Xiong M, Meng L, Zhang Z. TREM2 ectodomain and its soluble form in Alzheimer’s disease. J Neuroinflammation. 2020;17:204. doi:10.1186/s12974-020-01878-2
   PubMed Web of Science ®Google Scholar
• Suárez‐Calvet M, Kleinberger G, Araque MÁ, et al. sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. Embo Mol Med. 2016;8:466–476. doi:10.15252/emmm.201506123
   PubMed Web of Science ®Google Scholar
• Zhao L. CD33 in Alzheimer’s disease - biology, pathogenesis, and therapeutics: a mini-review. Gerontology. 2019;65:323–331. doi:10.1159/000492596
   PubMed Web of Science ®Google Scholar
• Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631–643. doi:10.1016/j.neuron.2013.04.014
   PubMed Web of Science ®Google Scholar
• Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, Lue LF. Association of CD33 polymorphism rs3865444 with Alzheimer’s disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging. 2015;36:571–582. doi:10.1016/j.neurobiolaging.2014.09.023
   PubMed Web of Science ®Google Scholar
• Malik M, Chiles JR, Xi HS, et al. Genetics of CD33 in Alzheimer’s disease and acute myeloid leukemia. Hum Mol Genet. 2015;24:3557–3570. doi:10.1093/hmg/ddv092
   PubMed Web of Science ®Google Scholar
• Raj T, Ryan KJ, Replogle JM, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer’s disease susceptibility. Hum Mol Genet. 2014;23:2729–2736. doi:10.1093/hmg/ddt666
   PubMed Web of Science ®Google Scholar
• Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43:436–441. doi:10.1038/ng.801
   PubMed Web of Science ®Google Scholar
• Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43:429–435. doi:10.1038/ng.803
   PubMed Web of Science ®Google Scholar
• Shen XN, Niu LD, Wang YJ, et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90:590–598. doi:10.1136/jnnp-2018-319148
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Bendlin BB. Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26:296–308. doi:10.1038/s41380-020-0721-9
   PubMed Web of Science ®Google Scholar
• Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies. J Neuroinflammation. 2017;14:118. doi:10.1186/s12974-017-0893-7
   PubMed Web of Science ®Google Scholar
• Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68:903–912. doi:10.1016/j.biopsych.2010.08.025
   PubMed Web of Science ®Google Scholar
• Janelidze S, Hertze J, Zetterberg H, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3:12–20. doi:10.1002/acn3.266
   PubMed Web of Science ®Google Scholar
• Rosen C, Andersson CH, Andreasson U, et al. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2014;4:297–304. doi:10.1159/000362164
   PubMedGoogle Scholar
• Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867–e877. doi:10.1212/WNL.0000000000006082
   PubMed Web of Science ®Google Scholar
• Zhou R, Ji B, Kong Y, et al. PET imaging of neuroinflammation in Alzheimer’s Disease. Front Immunol. 2021;12:739130. doi:10.3389/fimmu.2021.739130
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu K, Shao T, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharm Sin B. 2021;11:373–393. doi:10.1016/j.apsb.2020.08.006
   PubMed Web of Science ®Google Scholar
• Malpetti M, Kievit RA, Passamonti L, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease. Brain. 2020;143:1588–1602. doi:10.1093/brain/awaa088
   PubMed Web of Science ®Google Scholar
• Passamonti L, Tsvetanov KA, Jones PS, et al. Neuroinflammation and functional connectivity in Alzheimer’s disease: interactive influences on cognitive performance. J Neurosci. 2019;39:7218–7226. doi:10.1523/JNEUROSCI.2574-18.2019
   PubMed Web of Science ®Google Scholar
• Parbo P, Ismail R, Hansen KV, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain. 2017;140:2002–2011. doi:10.1093/brain/awx120
   PubMed Web of Science ®Google Scholar
• Andoh M, Koyama R. Microglia regulate synaptic development and plasticity. Dev Neurobiol. 2021;81:568–590. doi:10.1002/dneu.22814
   PubMed Web of Science ®Google Scholar
• Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712–716. doi:10.1126/science.aad8373
   PubMed Web of Science ®Google Scholar
• Decourt B, Lahiri DK, Sabbagh MN. Targeting tumor necrosis factor alpha for Alzheimer’s disease. Curr Alzheimer Res. 2017;14:412–425. doi:10.2174/1567205013666160930110551
   PubMed Web of Science ®Google Scholar
• MacEwan DJ. TNF ligands and receptors–a matter of life and death. Br J Pharmacol. 2002;135:855–875. doi:10.1038/sj.bjp.0704549
   PubMed Web of Science ®Google Scholar
• Shi JQ, Shen W, Chen J, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011;1368:239–247. doi:10.1016/j.brainres.2010.10.053
   PubMed Web of Science ®Google Scholar
• Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochem Int. 2014;72:10–13. doi:10.1016/j.neuint.2014.04.001
   PubMed Web of Science ®Google Scholar
• Dong Y, Fischer R, Naude PJ, et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proc Natl Acad Sci USA. 2016;113:12304–12309. doi:10.1073/pnas.1605195113
   PubMed Web of Science ®Google Scholar
• MacPherson KP, Sompol P, Kannarkat GT, et al. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol Dis. 2017;102:81–95. doi:10.1016/j.nbd.2017.02.010
   PubMed Web of Science ®Google Scholar
• Sama DM, Mohmmad AH, Furman JL, et al. Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS One. 2012;7:e38170. doi:10.1371/journal.pone.0038170
   PubMed Web of Science ®Google Scholar
• Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med. 2018;215:745–760. doi:10.1084/jem.20171529
   PubMed Web of Science ®Google Scholar
• Zhong L, Xu Y, Zhuo R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat Commun. 2019;10:1365. doi:10.1038/s41467-019-09118-9
   PubMed Web of Science ®Google Scholar
• Lee SH, Meilandt WJ, Xie L, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron. 2021;109:1283–1301. doi:10.1016/j.neuron.2021.02.010
   PubMed Web of Science ®Google Scholar
• Price BR, Sudduth TL, Weekman EM, et al. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation. 2020;17:238. doi:10.1186/s12974-020-01915-0
   PubMed Web of Science ®Google Scholar
• Wang S, Mustafa M, Yuede CM, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217. doi:10.1084/jem.20200785
   Web of Science ®Google Scholar
• Griciuc A, Federico AN, Natasan J, et al. Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet. 2020;29:2920–2935. doi:10.1093/hmg/ddaa179
   PubMed Web of Science ®Google Scholar
• Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. 2000;20:5709–5714. doi:10.1523/JNEUROSCI.20-15-05709.2000
   PubMed Web of Science ®Google Scholar
• Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci. 2003;23:7504–7509. doi:10.1523/JNEUROSCI.23-20-07504.2003
   PubMed Web of Science ®Google Scholar
• Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22:2246–2254. doi:10.1523/JNEUROSCI.22-06-02246.2002
   PubMed Web of Science ®Google Scholar
• Sung S, Yang H, Uryu K, et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer’s disease. Am J Pathol. 2004;165:2197–2206. doi:10.1016/s0002-9440(10)63269-5
   PubMed Web of Science ®Google Scholar
• Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain. 2008;131:651–664. doi:10.1093/brain/awn008
   PubMed Web of Science ®Google Scholar
• Ettcheto M, Sanchez-Lopez E, Cano A, et al. Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice. Cell Biosci. 2021;11:141. doi:10.1186/s13578-021-00646-w
   PubMed Web of Science ®Google Scholar
• de Oliveira J, Kucharska E, Garcez ML, et al. Inflammatory cascade in Alzheimer’s disease pathogenesis: a review of experimental findings. Cells-Basel. 2021;10. doi:10.3390/cells10102581
   Google Scholar
• Bachstetter AD, Xing B, de Almeida L. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta). J Neuroinflammation. 2011;8:79. doi:10.1186/1742-2094-8-79
   PubMed Web of Science ®Google Scholar
• Munoz L, Ranaivo HR, Roy SM, et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer’s disease mouse model. J Neuroinflammation. 2007;4:21. doi:10.1186/1742-2094-4-21
   PubMed Web of Science ®Google Scholar
• Hu W, Ralay RH, Roy SM. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett. 2007;17:414–418. doi:10.1016/j.bmcl.2006.10.028
   PubMed Web of Science ®Google Scholar
• Bachstetter AD, Norris CM, Sompol P, et al. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer’s disease-related pathology. J Neurosci. 2012;32:10201–10210. doi:10.1523/JNEUROSCI.1496-12.2012
   PubMed Web of Science ®Google Scholar
• Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003;301:1895–1898. doi:10.1126/science.1081297
   PubMed Web of Science ®Google Scholar
• Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020;11:1683. doi:10.1038/s41467-020-15436-0
   PubMed Web of Science ®Google Scholar
• Jordan F, Quinn TJ, McGuinness B, et al. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev. 2020;4:D11459. doi:10.1002/14651858.CD011459.pub2
   Web of Science ®Google Scholar
• Reading CL, Ahlem CN, Murphy MF. NM101 Phase III study of NE3107 in Alzheimer’s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021;11:289–298. doi:10.2217/nmt-2021-0022
   PubMed Web of Science ®Google Scholar
• Seo EJ, Fischer N, Efferth T. Phytochemicals as inhibitors of NF-kappaB for treatment of Alzheimer’s disease. Pharmacol Res. 2018;129:262–273. doi:10.1016/j.phrs.2017.11.030
   PubMed Web of Science ®Google Scholar
• Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28:110–113. doi:10.1097/jcp.0b013e318160862c
   PubMed Web of Science ®Google Scholar
• Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4:43. doi:10.1186/alzrt146
   PubMed Web of Science ®Google Scholar
• Small GW, Siddarth P, Li Z. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry. 2018;26:266–277. doi:10.1016/j.jagp.2017.10.010
   PubMed Web of Science ®Google Scholar
• Gajera CR, Fernandez R, Postupna N, et al. Mass synaptometry: applying mass cytometry to single synapse analysis. Methods Mol Biol. 2022;2417:69–88. doi:10.1007/978-1-0716-1916-2_6
   PubMedGoogle Scholar